Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12260740 | 0.86 | KMT2A (0.60) | KMT2AL3MBTL1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL17749697 | 0.85 | KMT2A (0.58) | KMT2AL3MBTL1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL2378215 | 0.85 | KMT2A (0.75) | KMT2AL3MBTL1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL30073534 | 0.85 | KMT2A (0.58) | KMT2AL3MBTL1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL28534582 | 0.83 | RXFP1 (0.51) | SMN1; SMN2ALDH1A1LMNAPOLBMAPT | |
| SCHEMBL4462435 | 0.82 | KMT2A (0.61) | KMT2AL3MBTL1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL17749759 | 0.79 | KMT2A (0.58) | KMT2AL3MBTL1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL13983152 | 0.77 | KDM4E (0.53) | KMT2AL3MBTL1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL11722513 | 0.76 | CA12 (0.70) | KMT2ASMN1; SMN2ALDH1A1LMNAPOLB | |
| SCHEMBL9760661 | 0.75 | MAPT (0.77) | KMT2AL3MBTL1SMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132495-A1 | Pyrazole Compounds that Modulate the Activity of Cdk, Gsk and Aurora Kinases | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132495-A1 | Pyrazole Compounds that Modulate the Activity of Cdk, Gsk and Aurora Kinases | CDK3, CDK1, AURKA | KMT2A 726/4885L3MBTL1 2376/4885SMN1; SMN2 2569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.